Back

EUR/GBP Price Analysis: Struggles near 100-DMA, around 0.9030 region

  • EUR/GBP extended Friday’s rejection slide from over one-month-old descending channel resistance.
  • Bearish traders might now aim to test an important support near the key 0.9000 psychological mark.
  • A sustained strength beyond the 0.9100 mark will now be seen as a fresh trigger for bullish traders.

The EUR/GBP cross witnessed some heavy selling on Monday and extended the previous session's rejection slide from a resistance marked by the top end of over one-month-old descending channel.

The downfall was sponsored by a strong pickup in demand for the British pound, with bears making a fresh attempt to extend the downward trajectory further below the 100-day SMA support. The mentioned support is followed by the key 0.9000 psychological mark, which if broken decisively should pave the way for further weakness.

The EUR/GBP cross might then accelerate the slide towards challenging the trend-channel support, which is currently pegged near the 0.8930-25 region. A convincing breakthrough will be seen as a fresh trigger for bearish traders and set the stage for an extension of the recent pullback from the vicinity of the 0.9300 mark.

Meanwhile, technical indicators on the daily chart – though have been struggling to gain any meaningful traction – are still far from confirming the near-term bearish outlook. Hence, any subsequent downfall might continue to attract some dip-buying and remain limited amid persistent Brexit-related uncertainties.

On the flip side, the 0.9070 horizontal zone now seems to act as an immediate hurdle ahead of the trend-channel resistance, around the 0.9100 round-figure mark. Bulls might wait for a sustained move beyond the mentioned barrier before positioning for a move towards the 0.9155-60 intermediate resistance en-route the 0.9200 mark.

EUR/GBP daily chart

fxsoriginal

Technical levels to watch

 

USD/CAD Price Analysis: Path of least resistance is to the downside

USD/CAD has bounced-off a dip to the weekly lows of 1.3169 but the outlook doesn’t appear constructive in the near-term. Despite the quick retracement
了解更多 Previous

S&P 500 Futures: Tests 3,500 after Pharmamar says Aplidin drug is enormously promising in treating COVID-19

With the global COVID-19 count topping 40 million, amid the latest surge in the European coronavirus cases, Spanish pharmaceutical company PharmaMar c
了解更多 Next